15 research outputs found
Backreaction in Acoustic Black Holes
The backreaction equations for the linearized quantum fluctuations in an
acoustic black hole are given. The solution near the horizon, obtained within a
dimensional reduction, indicates that acoustic black holes, unlike
Schwarzschild ones, get cooler as they radiate phonons. They show remarkable
analogies with near-extremal Reissner-Nordstrom black holes.Comment: 4 pages, revtex, 1 figure. revised version, published in pr
On the design and development of emulation platforms for NFV-based infrastructures
Network Functions Virtualisation (NFV) presents several advantages over traditional network architectures, such as flexibility, security, and reduced CAPEX/OPEX. In traditional middleboxes, network functions are usually executed on specialised hardware (e.g., firewall, DPI). Virtual Network Functions (VNFs) on the other hand, are executed on commodity hardware, employing Software Defined Networking (SDN) technologies (e.g., OpenFlow, P4). Although platforms for prototyping NFV environments have emerged in recent years, they still present limitations that hinder the evaluation of NFV scenarios such as fog computing and heterogeneous networks. In this work, we present NIEP: a platform for designing and testing NFV-based infrastructures and VNFs. NIEP consists of a network emulator and a platform for Click-based VNFs development. NIEP provides a complete NFV emulation environment, allowing network operators to test their solutions in a controlled scenario prior to deployment in production networks
Timed rise from floor as a predictor of disease progression in Duchenne muscular dystrophy: An observational study
The role of timed items, and more specifically, of the time to rise from the floor, has been reported as an early prognostic factor for disease progression and loss of ambulation. The aim of our study was to investigate the possible effect of the time to rise from the floor test on the changes observed on the 6MWT over 12 months in a cohort of ambulant Duchenne boys.A total of 487 12-month data points were collected from 215 ambulant Duchenne boys. The age ranged between 5.0 and 20.0 years (mean 8.48 ±2.48 DS).The results of the time to rise from the floor at baseline ranged from 1.2 to 29.4 seconds in the boys who could perform the test. 49 patients were unable to perform the test at baseline and 87 at 12 month The 6MWT values ranged from 82 to 567 meters at baseline. 3 patients lost the ability to perform the 6mwt at 12 months. The correlation between time to rise from the floor and 6MWT at baseline was high (r = 0.6, p<0.01).Both time to rise from the floor and baseline 6MWT were relevant for predicting 6MWT changes in the group above the age of 7 years, with no interaction between the two measures, as the impact of time to rise from the floor on 6MWT change was similar in the patients below and above 350 m. Our results suggest that, time to rise from the floor can be considered an additional important prognostic factor of 12 month changes on the 6MWT and, more generally, of disease progression
Efficacy and safety data in elderly patients with metastatic renal cell carcinoma included in the nivolumab Expanded Access Program (EAP) in Italy
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.
AIM:
Considering the unmet need for the counseling of cancer patients treated with immune checkpoint inhibitors (CKI) about influenza vaccination, an explorative study was planned to assess flu vaccine efficacy in this population.
METHODS:
INVIDIa was a retrospective, multicenter study, enrolling consecutive advanced cancer outpatients receiving CKI during the influenza season 2016-2017.
RESULTS:
Of 300 patients, 79 received flu vaccine. The incidence of influenza syndrome was 24.1% among vaccinated, versus 11.8% of controls; odds ratio: 2.4; 95% CI: 1.23-4.59; p = 0.009. The clinical ineffectiveness of vaccine was more pronounced among elderly: 37.8% among vaccinated patients, versus 6.1% of unvaccinated, odds ratio: 9.28; 95% CI: 2.77-31.14; p < 0.0001.
CONCLUSION:
Although influenza vaccine may be clinically ineffective in advanced cancer patients receiving CKI, it seems not to negatively impact the efficacy of anticancer therapy
Prognostic significance of host immune status in patients with late relapsing renal cell carcinoma treated with targeted therapy
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real-world results from an expanded access programme
ObjectiveTo report the safety and efficacy results of patients enrolled in the Italian Nivolumab Renal Cell Cancer Expanded Access Programme.
Patients and MethodsPatients with metastatic renal cell cancer (mRCC) previously treated with agents targeting the vascular endothelial growth factor pathway were eligible to receive nivolumab 3mg/kg once every 2weeks. Patients included in the analysis had received 1 dose of nivolumab and were monitored for adverse events (AEs) using Common Terminology Criteria for Adverse Events (CTCAE) v.4.0.
ResultsA total of 389 patients were enrolled between July 2015 and April 2016, of whom 18% were aged 75years, 6.7% had non-clear cell RCC, 49.6% had bone and 8.2% brain metastases, and 79% had received 2 previous lines of therapy. The most common any-grade treatment-related AEs were fatigue (13%) and rash (9%). Twenty-two patients (5.7%) discontinued treatment because of AEs. There were no treatment-related deaths. The objective response rate was 23.1%. At a median follow-up of 12months, the median progression-free survival was 4.5months (95% confidence interval 3.7-6.2) and the 12-month overall survival rate was 63%. Similar survival rates were reported among patients with non-clear-cell histology, elderly patients, those with bone and/or brain metastases, and those who had received prior first-line sunitinib or pazopanib, or prior everolimus.
ConclusionThe safety and efficacy observed were consistent with those reported in the pivotal Checkmate 025 trial. Results in patients with non-clear-cell mRCC who were elderly, pretreated with everolimus, and had bone and/or brain metastases encourage the use of nivolumab in these categories of patient